 |
市場調查報告書
商品編碼
1944726
全球藥物篩檢市場按產品類型、檢體類型、藥物類型、最終用戶和地區分類－預測至2030年Drug Screening Market by Offering (On-site Testing, Rapid Testing, Analytical ), Sample, Drug, End User - Global Forecast to 2030 |
||||||
價格
全球藥物篩檢市場預計將從 2025 年的 103.6 億美元成長到 2030 年的 212.9 億美元，複合年成長率為 15.5%。
市場成長主要受政府監管力度加大以及交通運輸、建築和製造等安全關鍵產業風險導向檢測的推廣應用所驅動。而全球毒品使用量的上升也是推動市場成長的因素之一。到2023年，全球將有約3.16億人吸毒，且吸毒率的成長速度超過人口成長速度。這增加了職場和公共道路上駕駛員受損的風險。與毒品相關的駕駛能力受損是道路交通事故（RTI）的重要因素，每年造成約130萬人死亡，其中93%發生在低收入和中等收入國家。這種情況進一步凸顯了在全球範圍內開展路邊和事故後毒品檢測項目的必要性。
| 調查範圍 | |
|---|---|
| 調查期 | 2024-2030 |
| 基準年 | 2024 |
| 預測期 | 2025-2030 |
| 目標單元 | 金額（十億美元） |
| 部分 | 按提供的產品、檢體類型、藥物類型、最終用戶和地區分類 |
| 目標區域 | 北美、歐洲、亞太地區、拉丁美洲、中東和非洲 |
在美國，2023年職場事故後藥物檢測陽性率達10.4%，其中大麻檢測陽性率上升至7.5%，創25年來新高。這表明成熟市場存在類似的風險模式，並預示著隨機檢測和事故後檢測的普及速度正在加快。因此，雇主和監管機構優先考慮快速、合法有效的篩檢和確認檢測方案，而醫院也越來越依賴高通量液相層析質譜聯用（LC-MS）確認毒理學檢測來支持關鍵的臨床決策。同時，口腔液、唾液和毛髮檢測的廣泛應用正在重塑檢測通訊協定，因為這些檢測方法篡改風險較低，且能更準確地檢測近期用藥情況。這迫使各機構升級傳統的藥物篩檢技術，以應對不斷上升的工傷率和日益嚴格的認證標準。
預計在預測期內，包括檢查室檢測服務和現場檢測服務在內的服務板塊將推動藥物篩檢市場的發展，因為各機構將繼續採用全面且管理完善的檢測服務。檢查室檢測服務有助於進行大量檢測、確證檢測並滿足監管要求，而現場檢測服務則可在所需地點進行快速檢測。合規性主導、隨機和多組檢測項目的日益普及，以及口腔液和毛髮等替代檢體類型的廣泛應用，都在推動對專業服務供應商的需求。營運趨勢也印證了這一點，2023 年 Quest Diagnostics 藥物檢測指數顯示，員工檢測作弊案例急劇增加，顯示對專業管理和確證檢測服務的需求日益成長，且複雜性也隨之增加。此外，2025 年的職場趨勢表明，擴充性、合規性和整合報告是促使各機構選擇外包藥物檢測而非內部管理的關鍵促進因素。在檢測量和成本不斷上升的情況下，各機構正在積極採用擴充性、合規且以服務為導向的藥物篩檢解決方案，這支撐了服務市場的強勁成長。 2022年12月，歐米茄實驗室在其位於加拿大安大略省的先進實驗室推出了尿液藥物檢測服務。該實驗室將於2023年1月3日開始提供尿液藥物檢測服務，作為對其分子檢測服務的補充。
全球藥物篩檢市場的成長主要受非法藥物使用增加、職業安全與健康問題以及醫療保健和法律體系變革的驅動。據估計，全球每年約有9%的15至64歲成年人使用非法藥物，其中大麻、鴉片類藥物和興奮劑最為普遍。每年約有60萬人死於藥物相關疾病，凸顯了這個嚴重的公共衛生問題。在歐洲，8.4%的成年人有大麻使用問題，而藥物相關死亡人數持續上升，主要原因是鴉片類藥物和多種藥物濫用。這些因素促使全球範圍內，尤其是在安全至關重要的行業，擴大了屍檢、隨機和定期職場藥物篩檢的範圍。近年來，非侵入性檢體類型（例如口腔液和毛髮）的日益普及，以及路邊和執法機關藥物檢測的擴展，提高了藥物檢測的準確性，並有效防止了檢體篡改。
藥物濫用趨勢的上升以及對外包檢測的結構性需求正在推動亞太市場的發展。在澳大利亞，2022-2023年度全國藥物管製家庭調查估計，每天有180萬人吸煙，過去12個月內有250萬人使用過大麻，100萬人使用過可卡因，660萬人存在危險飲酒行為，這反映出醫療保健和職場場所對臨床毒理學和藥物監測服務的持續需求。此外，包括可卡因和電子菸在內的非法藥物使用在年輕人和女性中呈上升趨勢，使得檢測目標人口不再局限於傳統的高風險群體。在印度，情況更為嚴峻。全國調查數據顯示，目前有14.6%的人口（約1.6億人）飲酒，3,100萬人使用大麻，超過2,000萬人使用鴉片類藥物，約600萬人需要接受治療服務。此外，有 1,180 萬人濫用鴉片類藥物，估計有 85 萬人注射毒品，這使得醫院、復健機構和公共衛生機構對檢查室毒理學檢測的需求持續存在。
Labcorp（美國）、Quest Diagnostics Incorporated（美國）和 Abbott（美國）是藥物篩檢市場的主要企業。
- 該研究對藥物篩檢市場的主要企業進行了深入的競爭分析，包括公司簡介、近期發展和關鍵市場策略。
調查對象
本報告按產品/服務類型、檢體類型、藥物類型、最終用戶和地區對市場進行分類。報告詳細資訊闡述了影響藥物篩檢市場成長的關鍵因素，包括促進因素、限制因素、挑戰和機會。該報告還對主要行業參與企業進行了深入分析，包括其業務概況、解決方案、服務、關鍵策略、合約、合作關係和協議、新產品和服務發布、併購以及與藥物篩檢市場相關的最新發展。此外，該報告還對藥物篩檢市場生態系統中新興的Start-Ups進行了競爭分析。
購買本報告的好處
本報告為市場領導和新參與企業提供藥物篩檢市場及其細分市場最準確的收入估計值，幫助相關人員了解競爭格局，並為最佳化業務定位和製定合適的打入市場策略提供洞察。報告還概述了市場趨勢，並提供了關鍵市場促進因素、限制、挑戰和機會的資訊。
本報告深入分析了以下內容：
- 對關鍵促進因素（非法藥物和酒精消費量的增加、強制進行藥物和酒精檢測的嚴格法律的實施、藥物篩檢產品和服務監管核准數量的增加）、阻礙因素（伊斯蘭國家禁止飲酒、禁止在職場進行藥物檢測）、機會（口腔液檢測的日益普及、職場採用基於指紋的藥物檢測、新興經濟體的高成長機會）和挑戰（對呼吸檢測設備的準確性和特異性的擔憂、藥物篩檢中的假陽性和假陰性結果）的分析正在影響藥物篩檢市場的成長。
- 產品開發與創新：深入分析藥物篩檢市場的未來技術趨勢、研發活動以及新產品和服務發布。
- 市場發展：提供盈利市場的全面資訊。該報告分析了各地區的藥物篩檢市場。
- 市場多元化：關於藥物篩檢市場的新產品和服務、前沿地區、近期趨勢和投資的全面訊息
- 競爭格局分析：對藥物篩檢市場主要參與者（如 LabCorp（美國）、Quest 篩檢 Incorporated（美國）、Abbott（美國）、OraSure Technologies Inc.（美國）、Alfa Scientific Designs Inc.（美國）、Thermo Fisher Scientific Inc.（美國）和 Dragerwerk AG Designs Inc.（美國）、Thermo Fisher Scientific Inc.（美國）和 Dragerwerk AG 主要企業 KGaA（德國市場成長）進行詳細的市場成長率評估、市場成長）。
目錄
第1章 引言
第2章執行摘要
第3章重要考察
第4章 市場概覽
- 市場動態
- 促進要素
- 抑制因素
- 機會
- 任務
- 未滿足的需求和閒置頻段
- 相互關聯的市場與跨產業機遇
- 1/2/3級參與企業的策略舉措
第5章 產業趨勢
- 波特五力分析
- 總體經濟指標
- 價值鏈分析
- 生態系分析
- 定價分析
- 2026-2027 年主要會議和活動
- 影響客戶業務的趨勢/顛覆性因素
- 投資和資金籌措方案
- 案例研究分析
- 2025年美國關稅對藥物檢測市場的影響
第6章：科技、專利和數位化/人工智慧應用帶來的策略顛覆
- 關鍵新興技術
- 互補技術
- 鄰近技術
- 技術/產品藍圖
- 專利分析
- 未來應用
- 人工智慧/生成式人工智慧對藥物篩檢市場的影響
第7章：顧客狀況與購買行為
- 決策流程
- 買方相關人員和採購評估標準
- 招募障礙和內部挑戰
- 來自各個終端使用者產業的未滿足需求
- 市場盈利
第8章：監理環境
- 地方法規和合規性
- 監管機構、政府機構和其他組織
- 法規結構
- 業界標準
9. 藥物篩檢市場（依產品/服務分類）
- 服務
- 產品
第10章 藥物篩檢市場（依檢體類型分類）
- 尿液樣本
- 呼吸樣本
- 口腔液樣本
- 頭髮樣本
- 其他樣本
第11章 藥物篩檢市場（依藥物類型分類）
- 大麻
- 酒精
- 古柯鹼
- 鴉片類藥物
- 安非他命和甲基安非他命
- 其他
12. 按最終用戶分類的藥物篩檢市場
- 藥物檢測實驗室
- 職場
- 刑事司法系統與執法機關
- 醫院
- 藥物治療中心
- 個人用戶
- 疼痛管理中心
- 學校和大學
- 其他
13. 各地區藥物篩檢市場
- 北美洲
- 北美宏觀經濟展望
- 美國
- 加拿大
- 歐洲
- 歐洲宏觀經濟展望
- 德國
- 法國
- 英國
- 義大利
- 西班牙
- 其他
- 亞太地區
- 亞太宏觀經濟展望
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 其他
- 拉丁美洲
- 拉丁美洲宏觀經濟展望
- 巴西
- 墨西哥
- 其他
- 中東和非洲
- 中東和非洲宏觀經濟展望
- 海灣合作理事會國家
- 南非
- 其他
第14章 競爭格局
- 概述
- 主要參與企業的策略/優勢
- 2020-2024年收入分析
- 2024年市佔率分析
- 品牌對比
- 估值和財務指標
- 公司估值矩陣：主要參與企業，2024 年
- 公司估值矩陣：Start-Ups/中小企業，2024 年
- 競爭場景
第15章 公司簡介
- 主要參與企業
- LABCORP
- QUEST DIAGNOSTICS INCORPORATED
- ABBOTT
- ORASURE TECHNOLOGIES INC.
- ALFA SCIENTIFIC DESIGNS INC.
- THERMO FISHER SCIENTIFIC INC.
- DRAGERWERK AG & CO. KGAA
- LIFELOC TECHNOLOGIES, INC.
- MPD INC.
- OMEGA LABORATORIES, INC.
- PREMIER BIOTECH, INC.
- PSYCHEMEDICS CORPORATION
- F. HOFFMANN-LA ROCHE LTD.
- SHIMADZU CORPORATION
- SIEMENS HEALTHINEERS AG
- BIO-RAD LABORATORIES, INC.
- 其他公司
- CAREHEALTH AMERICA CORP.
- ACCUSOURCEHR, INC.
- CORDANT HEALTH SOLUTIONS
- ADVACARE PHARMA
- ACM GLOBAL LABORATORIES
- MILLENNIUM HEALTH
- CLINICAL REFERENCE LABORATORY, INC.
- INTOXIMETERS
- INTOXALOCK
第16章調查方法
第17章附錄
Product Code: MD 3239
The global drug screening market is projected to reach USD 21.29 billion by 2030 from USD 10.36 billion in 2025, at a CAGR of 15.5%. The drug screening market is being driven by expanding government mandates and risk-based testing across safety-sensitive sectors such as transportation, construction, and manufacturing. This growth is underpinned by rising global substance use. Around 316 million people worldwide used drugs in 2023, a rate increasing faster than population growth, heightening impairment risks in workplaces and on public roads. Drug-related impairment is a critical contributor to road traffic injuries (RTIs), which cause approximately 1.3 million deaths annually, with 93% occurring in low- and middle-income countries, reinforcing the need for roadside and post-incident drug testing programs globally.
| Scope of the Report | |
|---|---|
| Years Considered for the Study | 2024-2030 |
| Base Year | 2024 |
| Forecast Period | 2025-2030 |
| Units Considered | Value (USD billion) |
| Segments | Offering, Sample Type, Drug Type, and End User |
| Regions covered | North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
In the US, post-accident workplace drug positivity reached 10.4% in 2023, with marijuana positivity rising to a 25-year high of 7.5%, illustrating similar risk patterns in mature markets and accelerating adoption of random and post-incident testing. As a result, employers and regulators are prioritizing fast, legally defensible screening and confirmatory solutions, while hospitals increasingly rely on high-throughput LC-MS definitive toxicology testing to support critical clinical decisions. At the same time, broader acceptance of oral fluid, saliva, and hair testing is reshaping testing protocols by enabling more accurate detection of recent drug use with lower tampering risk, compelling organizations to upgrade conventional drug screening technologies in response to rising impairment rates and stricter accreditation standards.
"By offering, services segment to account for largest market share"
Based on offering, the services segment, which includes laboratory testing services and onsite testing services, is anticipated to fuel the drug screening market over the forecast period, as organizations continue to adopt comprehensive and managed testing services. Laboratory testing services assist in dealing with a large number of tests, confirmatory tests, and regulatory requirements, whereas onsite testing services facilitate rapid testing at the point of need. The rising trend of compliance-driven, random, and multi-panel testing programs, as well as the increasing use of alternative specimen types such as oral fluid and hair, is driving the demand for specialized service providers. This is also evident in the operational trends, which highlight that, according to the 2023 Quest Diagnostics Drug Testing Index, incidents of workforce test cheating jumped sharply, indicating the growing complexity and need for expert management and confirmatory services. In addition, workplace trends in 2025 highlight that scalability, regulatory compliance, and integrated reporting are key drivers for organizations outsourcing drug testing, rather than managing testing programs in-house. As testing volumes and expenses increase, organizations are increasingly adopting scalable, compliant, and service-oriented drug screening solutions, which support robust growth in the services market. In December 2022, Omega Laboratories launched the Urine Drugs of Abuse Testing Services in its state-of-the-art laboratory in Ontario, Canada. The laboratory offered urine drug testing from January 3, 2023, to complement its molecular testing.
"By end user, drug testing laboratories accounted for largest share of drug screening market in 2024."
The global drug screening market is fueled by the growing prevalence of illicit drug use, occupational health and safety concerns, and changing medical and legal needs. Globally, it is estimated that 9% of the adult population between 15 and 64 years of age uses illicit drugs every year, with cannabis, opioids, and stimulants being the most prevalent, while drug-related deaths contribute to approximately 0.6 million deaths annually, emphasizing a substantial public health problem. In Europe, cannabis use is a problem for 8.4 % of adults, and drug-related deaths continue to increase, largely due to opioids and polysubstance use. These factors are fueling increasing post-incident, random, and routine drug screening in the workplace in safety-sensitive industries worldwide. The increasing use of non-invasive specimen types, such as oral fluid and hair, as well as the expansion of roadside and law enforcement drug testing, is improving the detection of recent drug use and preventing sample tampering.
"APAC to witness the highest growth rate during the forecast period"
The increasing prevalence of substance use and the structural need for outsourced laboratory testing are driving the market in Asia Pacific. In Australia, the 2022-2023 National Drug Strategy Household Survey estimates that 1.8 million people smoke daily, 2.5 million people have used cannabis in the past 12 months, 1.0 million people have used cocaine, and 6.6 million people engage in risky alcohol consumption, reflecting the continued demand for clinical toxicology and substance monitoring services in healthcare and occupational settings. Moreover, illicit substance use, including cocaine and e-cigarettes, is rising among young adults and women, expanding the tested population beyond the traditional high-risk group. In India, the numbers are even more substantial. National survey data show that 14.6% of the population (approximately 160 million people) are current alcohol users, 31 million people use cannabis, and over 20 million people use opioids, with nearly 6 million people in need of treatment services. Furthermore, 11.8 million people misuse sedatives, and an estimated 850,000 people inject drugs, representing a continued need for laboratory-based toxicology testing in hospitals, rehabilitation facilities, and public health settings.
The breakdown of primary participants is as given below:
- By Company Type - Tier 1: 60%, Tier 2: 30%, and Tier 3: 10%
- By Designation - C-level: 30%, Director-level: 50%, and Others: 20%
- By Region - North America: 45%, Europe: 20%, Asia Pacific: 25%, Rest of the world: 10%.
Labcorp (US), Quest Diagnostics Incorporated (US), and Abbott (US) are some of the key players in the drug screening market.
- The study includes an in-depth competitive analysis of these key players in the drug screening market, with their company profiles, recent developments, and key market strategies.
Research Coverage
This research report categorizes the drug screening market by offering (products & services), sample type (urine samples, breath samples, oral fluid samples, hair samples, other samples), drug type (cannabis, alcohol, cocaine, opioids, amphetamine and methamphetamine, other drugs) end user (drug testing laboratories, workplaces, criminal justice systems and law enforcement agencies, hospitals, drug treatment centers, individual users, pain management centers, schools and colleges, other end users), and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the drug screening market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; contracts, partnerships, agreements, new product & service launches, mergers & acquisitions, and recent developments associated with the drug screening market. Competitive analysis of upcoming startups in the drug screening market ecosystem is covered in this report.
Reasons to buy this report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the drug screening market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
- Analysis of key drivers (Growing consumption of illicit drugs and alcohol, Enforcement of stringent laws mandating drug and alcohol testing, Increasing number of regulatory approvals for drug screening products and services) restraints (Ban on alcohol consumption in Islamic countries, Prohibition on workplace drug testing) opportunities (Popularity of oral fluid testing, Introduction of fingerprint-based drug testing at workplaces, High growth opportunities in emerging economies) challenges (Accuracy and specificity concerns in breathalyzers, False positive and negative results in drug screening) influencing the growth of the drug screening market
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the drug screening market
- Market Development: Comprehensive information about lucrative markets; the report analyses the drug screening market across varied regions.
- Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the drug screening market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like LabCorp (US), Quest Diagnostics Incorporated (US), Abbott (US), OraSure Technologies Inc. (US), Alfa Scientific Designs Inc. (US), Thermo Fisher Scientific Inc. (US), and Dragerwerk AG & Co. KGaA (Germany), among others, in the drug screening market
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 MARKET SCOPE
- 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
- 1.3.2 INCLUSIONS & EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.4 CURRENCY CONSIDERED
- 1.5 LIMITATIONS
- 1.6 STAKEHOLDERS
- 1.7 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
- 2.1 MARKET HIGHLIGHTS & KEY INSIGHTS
- 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
- 2.3 DISRUPTIVE TRENDS IN DRUG SCREENING MARKET
- 2.4 HIGH-GROWTH SEGMENTS
- 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
- 3.1 DRUG SCREENING MARKET OVERVIEW
- 3.2 DRUG SCREENING MARKET, BY OFFERING & REGION
- 3.3 DRUG SCREENING MARKET: GEOGRAPHIC SNAPSHOT
- 3.4 DRUG SCREENING MARKET: DEVELOPED VS. EMERGING ECONOMIES
4 MARKET OVERVIEW
- 4.1 INTRODUCTION
- 4.2 MARKET DYNAMICS
- 4.2.1 DRIVERS
- 4.2.1.1 Growing consumption of illicit drugs and alcohol
- 4.2.1.2 Enforcement of stringent laws mandating drug and alcohol testing
- 4.2.1.3 Increasing number of regulatory approvals for drug screening products & services
- 4.2.2 RESTRAINTS
- 4.2.2.1 Ban on alcohol consumption in Islamic countries
- 4.2.2.2 Prohibition on workplace drug testing
- 4.2.3 OPPORTUNITIES
- 4.2.3.1 Popularity of oral fluid testing
- 4.2.3.2 Introduction of fingerprint-based drug testing in workplaces
- 4.2.3.3 High growth opportunities in emerging economies
- 4.2.4 CHALLENGES
- 4.2.4.1 Accuracy and specificity concerns in breathalyzers
- 4.2.4.2 False positive and negative results in drug screening
- 4.2.1 DRIVERS
- 4.3 UNMET NEEDS & WHITE SPACES
- 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
- 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
- 5.1 PORTER'S FIVE FORCES ANALYSIS
- 5.1.1 BARGAINING POWER OF SUPPLIERS
- 5.1.2 BARGAINING POWER OF BUYERS
- 5.1.3 THREAT OF SUBSTITUTES
- 5.1.4 THREAT OF NEW ENTRANTS
- 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.2 MACROECONOMIC INDICATORS
- 5.2.1 INTRODUCTION
- 5.2.2 GDP TRENDS & FORECAST
- 5.2.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY
- 5.3 VALUE CHAIN ANALYSIS
- 5.4 ECOSYSTEM ANALYSIS
- 5.5 PRICING ANALYSIS
- 5.5.1 INDICATIVE PRICING OF DRUG SCREENING PRODUCTS & SERVICES, BY TYPE (2024)
- 5.5.2 INDICATIVE PRICING OF DRUG SCREENING PRODUCTS & SERVICES, BY REGION (2024)
- 5.6 KEY CONFERENCES & EVENTS, 2026-2027
- 5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
- 5.8 INVESTMENT & FUNDING SCENARIO
- 5.9 CASE STUDY ANALYSIS
- 5.10 IMPACT OF 2025 US TARIFFS ON DRUG SCREENING MARKET
- 5.10.1 INTRODUCTION
- 5.10.2 KEY TARIFF RATES
- 5.10.3 PRICE IMPACT ANALYSIS
- 5.10.4 IMPACT ON COUNTRY/REGION
- 5.10.4.1 US
- 5.10.4.2 Europe
- 5.10.4.3 Asia Pacific
- 5.10.5 IMPACT ON END-USE INDUSTRIES
- 5.10.5.1 Drug testing laboratories
- 5.10.5.2 Workplaces
- 5.10.5.3 Criminal justice systems & law enforcement agencies
- 5.10.5.4 Hospitals
- 5.10.5.5 Drug treatment centers
- 5.10.5.6 Individual users
- 5.10.5.7 Pain management centers
- 5.10.5.8 Schools & colleges
- 5.10.5.9 Other end users
6 STRATEGIC DISRUPTIONS THROUGH TECHNOLOGY, PATENTS, AND DIGITAL & AI ADOPTION
- 6.1 KEY EMERGING TECHNOLOGIES
- 6.1.1 LC-MS/MS & GC-MS-BASED CONFIRMATORY TESTING TECHNOLOGIES
- 6.1.2 AI-DRIVEN RESULT INTERPRETATION & QUALITY ASSURANCE TECHNOLOGIES
- 6.1.3 LABORATORY AUTOMATION & ROBOTICS TECHNOLOGIES
- 6.2 COMPLEMENTARY TECHNOLOGIES
- 6.2.1 MOBILE HEALTH (MHEALTH) & REMOTE COLLECTION TECHNOLOGIES
- 6.2.2 ANALYTICS & POPULATION-LEVEL DRUG USE SURVEILLANCE TOOLS
- 6.3 ADJACENT TECHNOLOGIES
- 6.3.1 FORENSIC CASE MANAGEMENT SYSTEMS
- 6.3.2 WORKFORCE BACKGROUND SCREENING/VERIFICATION SYSTEMS
- 6.4 TECHNOLOGY/PRODUCT ROADMAP
- 6.5 PATENT ANALYSIS
- 6.5.1 PATENT PUBLICATION TRENDS FOR DRUG SCREENING MARKET
- 6.5.2 INSIGHTS: JURISDICTION & TOP APPLICANT ANALYSIS
- 6.6 FUTURE APPLICATIONS
- 6.6.1 AI-ENABLED INTELLIGENT SCREENING AND RESULT INTERPRETATION
- 6.6.2 CONTINUOUS AND PREDICTIVE DRUG MONITORING APPLICATIONS
- 6.6.3 DECENTRALIZED, AT-HOME, AND POINT-OF-CARE SCREENING EXPANSION
- 6.6.4 INTEGRATED COMPLIANCE, FORENSIC, AND PUBLIC HEALTH INTELLIGENCE PLATFORMS
- 6.6.5 PERSONALIZED AND THERAPEUTIC DRUG SCREENING APPLICATIONS
- 6.7 IMPACT OF AI/GEN AI ON DRUG SCREENING MARKET
- 6.7.1 INTRODUCTION
- 6.7.2 MARKET POTENTIAL OF AI/GEN AI IN DRUG SCREENING MARKET
- 6.7.3 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION
- 6.7.3.1 AI-driven transformation of preclinical toxicology screening at PathAI
- 6.7.4 IMPACT OF AI/GEN AI ON INTERCONNECTED & ADJACENT ECOSYSTEMS
- 6.7.4.1 Laboratory & toxicology operations
- 6.7.4.2 Laboratory information systems (LIS) & compliance infrastructure
- 6.7.4.3 Clinical care, workplace safety, and monitoring programs
- 6.7.5 USER READINESS AND IMPACT ASSESSMENT
- 6.7.5.1 User readiness
- 6.7.5.1.1 User A: Clinical, reference, and toxicology laboratories
- 6.7.5.1.2 User B: Healthcare providers, employers, and forensic agencies
- 6.7.5.2 Impact assessment
- 6.7.5.2.1 User A: Clinical, reference, and toxicology laboratories
- 6.7.5.2.1.1 Implementation
- 6.7.5.2.1.2 Impact
- 6.7.5.2.2 User B: Healthcare providers, employers, and forensic agencies
- 6.7.5.2.2.1 Implementation
- 6.7.5.2.2.2 Impact
- 6.7.5.2.1 User A: Clinical, reference, and toxicology laboratories
- 6.7.5.1 User readiness
7 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
- 7.1 INTRODUCTION
- 7.2 DECISION-MAKING PROCESS
- 7.3 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
- 7.3.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 7.3.2 BUYING CRITERIA
- 7.4 ADOPTION BARRIERS & INTERNAL CHALLENGES
- 7.5 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
- 7.5.1 UNMET NEEDS
- 7.5.2 END-USER EXPECTATIONS
- 7.6 MARKET PROFITABILITY
8 REGULATORY LANDSCAPE
- 8.1 REGIONAL REGULATIONS & COMPLIANCE
- 8.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 8.1.2 REGULATORY FRAMEWORK
- 8.1.2.1 North America
- 8.1.2.2 Europe
- 8.1.2.3 Asia Pacific
- 8.1.2.4 Latin America
- 8.1.2.5 Middle East & Africa
- 8.1.3 INDUSTRY STANDARDS
9 DRUG SCREENING MARKET, BY OFFERING
- 9.1 INTRODUCTION
- 9.2 SERVICES
- 9.2.1 WORKFORCE DECENTRALIZATION, PANEL COMPLEXITY, AND LITIGATION-READY TESTING TO DRIVE SUSTAINED MARKET GROWTH
- 9.2.2 LABORATORY TESTING SERVICES
- 9.2.2.1 Ability to ensure analytical rigor and compliance with regulatory standards to drive demand
- 9.2.3 ON-SITE TESTING SERVICES
- 9.2.3.1 Ability to deliver rapid, point-of-care screening solutions to drive market growth
- 9.3 PRODUCTS
- 9.3.1 ANALYTICAL INSTRUMENTS MARKET, BY TYPE
- 9.3.1.1 Breathalyzers
- 9.3.1.1.1 Fuel-cell breathalyzers
- 9.3.1.1.1.1 Extremely high accuracy, sensitivity, and reliability to drive demand for fuel-cell breathalyzers
- 9.3.1.1.2 Semiconductor breathalyzers
- 9.3.1.1.2.1 Lower prices of semiconductor breathalyzers to drive adoption
- 9.3.1.1.3 Other breathalyzers
- 9.3.1.1.1 Fuel-cell breathalyzers
- 9.3.1.2 Immunoassay analyzers
- 9.3.1.2.1 Growing adoption of high-throughput immunoassay platforms to power modern toxicology
- 9.3.1.3 Chromatography instruments
- 9.3.1.3.1 Advantages such as precise, high-sensitivity analysis in forensic, clinical, and regulatory laboratories to fuel growth
- 9.3.1.1 Breathalyzers
- 9.3.2 ANALYTICAL INSTRUMENTS MARKET, BY MODALITY
- 9.3.2.1 Handheld breathalyzers
- 9.3.2.1.1 Critical role in delivering fast, accurate, and portable alcohol screening to support market growth
- 9.3.2.2 Benchtop breathalyzers
- 9.3.2.2.1 Growing use of benchtop breathalyzers for drug detection analysis to drive growth
- 9.3.2.1 Handheld breathalyzers
- 9.3.3 RAPID TESTING DEVICES
- 9.3.3.1 Urine testing devices
- 9.3.3.1.1 Drug testing cups
- 9.3.3.1.1.1 Reduced contact with urine sample to drive demand
- 9.3.3.1.2 Dip cards
- 9.3.3.1.2.1 Ability to provide qualitative results within minutes to propel market
- 9.3.3.1.3 Drug testing cassettes
- 9.3.3.1.3.1 Lower cost alternatives to drug testing cups and dip cards to boost adoption
- 9.3.3.1.1 Drug testing cups
- 9.3.3.2 Oral fluid testing devices
- 9.3.3.2.1 Rapid, non-invasive detection of recent drug use across workplace, clinical, and law enforcement settings to fuel growth
- 9.3.3.1 Urine testing devices
- 9.3.4 CONSUMABLES
- 9.3.4.1 Assay kits
- 9.3.4.1.1 Rapid, cost-effective, and high-throughput screening across drug testing applications to drive market
- 9.3.4.2 Sample collection devices
- 9.3.4.2.1 Reliable, tamper-resistant, and versatile drug testing across settings to support growth
- 9.3.4.3 Calibrators & controls
- 9.3.4.3.1 Ability to verify accuracy, precision, and reliability of screening and confirmatory test results to drive growth
- 9.3.4.4 Other consumables
- 9.3.4.1 Assay kits
- 9.3.1 ANALYTICAL INSTRUMENTS MARKET, BY TYPE
10 DRUG SCREENING MARKET, BY SAMPLE TYPE
- 10.1 INTRODUCTION
- 10.2 URINE SAMPLES
- 10.2.1 RECENT ADVANCES TO STRENGTHEN ACCURACY AND RELIABILITY IN URINE DRUG TESTING
- 10.3 BREATH SAMPLES
- 10.3.1 BREATH ALCOHOL TESTS TO REGISTER WIDE USAGE IN WORKPLACE TESTING AND LAW ENFORCEMENT APPLICATIONS
- 10.4 ORAL FLUID SAMPLES
- 10.4.1 NON-INVASIVE SAMPLE COLLECTION AND LOW CHANCE OF ADULTERATION TO SUPPORT USAGE OF ORAL FLUID SAMPLES
- 10.5 HAIR SAMPLES
- 10.5.1 ABILITY OF HAIR SAMPLES TO PROVIDE INSIGHTS INTO LONG-TERM DRUG USE TO BOOST MARKET
- 10.6 OTHER SAMPLES
11 DRUG SCREENING MARKET, BY DRUG TYPE
- 11.1 INTRODUCTION
- 11.2 CANNABIS
- 11.2.1 GROWING CANNABIS USE AND REGULATORY COMPLEXITY TO DRIVE SUSTAINED DEMAND FOR DRUG SCREENING SOLUTIONS
- 11.3 ALCOHOL
- 11.3.1 REGULATORY ENFORCEMENT AND TECHNOLOGY INNOVATION TO STRENGTHEN ALCOHOL SCREENING ADOPTION
- 11.4 COCAINE
- 11.4.1 SHIFT TOWARD RAPID, DEFENSIBLE DETECTION TO POSITION COCAINE AS PRIORITY DRUG IN MODERN SCREENING PANELS
- 11.5 OPIOIDS
- 11.5.1 EXPANDED OPIOID PANELS AND ADVANCED CONFIRMATORY TECHNOLOGIES TO REINFORCE OPIOID SCREENING AS HIGH PRIORITY
- 11.6 AMPHETAMINES & METHAMPHETAMINES
- 11.6.1 ADVANCED ANALYTICS AND DIFFERENTIATION TESTING TO REDEFINE AMPHETAMINE & METHAMPHETAMINE DETECTION
- 11.7 OTHER DRUGS
12 DRUG SCREENING MARKET, BY END USER
- 12.1 INTRODUCTION
- 12.2 DRUG TESTING LABORATORIES
- 12.2.1 ADVANCED ANALYTICS, AUTOMATION, AND EXPANDING FORENSIC AND CLINICAL DEMAND TO DRIVE MARKET GROWTH
- 12.3 WORKPLACES
- 12.3.1 RISING NUMBER OF DRUG ABUSE CASES TO INCREASE WORKPLACE TESTING
- 12.4 CRIMINAL JUSTICE SYSTEMS & LAW ENFORCEMENT AGENCIES
- 12.4.1 HIGH SUBSTANCE-USE PREVALENCE AND DUI RISKS TO DRIVE MANDATORY DRUG & ALCOHOL TESTING
- 12.5 HOSPITALS
- 12.5.1 RISING EMERGENCY ADMISSIONS, OPIOID OVERDOSES, AND PATIENT SAFETY MANDATES TO DRIVE STRONG DEMAND
- 12.6 DRUG TREATMENT CENTERS
- 12.6.1 RISING ADOPTION OF MEDICATION-ASSISTED TREATMENT, RELAPSE MONITORING, AND FENTANYL DETECTION TO DRIVE DEMAND
- 12.7 INDIVIDUAL USERS
- 12.7.1 GROWING SELF-MONITORING, HOME TESTING, AND RECOVERY ACCOUNTABILITY TO EXPANDING INDIVIDUAL USE OF SCREENING
- 12.8 PAIN MANAGEMENT CENTERS
- 12.8.1 OPIOID PRESCRIBING OVERSIGHT AND PATIENT SAFETY MANDATES TO DRIVE INCREASED DRUG SCREENING
- 12.9 SCHOOLS & COLLEGES
- 12.9.1 MODERN TESTING AND AWARENESS PROGRAMS TO STRENGTHEN DRUG ABUSE PREVENTION IN SCHOOLS & COLLEGES
- 12.10 OTHER END USERS
13 DRUG SCREENING MARKET, BY REGION
- 13.1 INTRODUCTION
- 13.2 NORTH AMERICA
- 13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
- 13.2.2 US
- 13.2.2.1 Regulatory enforcement and substance use prevalence drive drug screening market in US
- 13.2.3 CANADA
- 13.2.3.1 Public health surveillance, consumption trends, and enforcement & technological advancements to drive market
- 13.3 EUROPE
- 13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
- 13.3.2 GERMANY
- 13.3.2.1 Strengthening drug screening adoption through public health policy and technological modernization to support market growth
- 13.3.3 FRANCE
- 13.3.3.1 Regulatory enforcement, transport safety, and forensic modernization to shape drug screening market
- 13.3.4 UK
- 13.3.4.1 Community-embedded testing, criminal justice demand, and real-time drug surveillance to shape UK drug screening market
- 13.3.5 ITALY
- 13.3.5.1 Strengthening drug screening market through roadside enforcement and analytical innovation & institutional capacity
- 13.3.6 SPAIN
- 13.3.6.1 Expanding drug screening adoption through road safety programs to drive market growth
- 13.3.7 REST OF EUROPE
- 13.4 ASIA PACIFIC
- 13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
- 13.4.2 CHINA
- 13.4.2.1 Synthetic drug control and pharmaceutical innovation to drive drug screening market growth
- 13.4.3 JAPAN
- 13.4.3.1 Japan's aging population and advanced digital infrastructure to drive rapid adoption
- 13.4.4 INDIA
- 13.4.4.1 Alcohol dominance, opioid misuse, and India's role as global pharmaceutical hub to drive drug screening market growth
- 13.4.5 AUSTRALIA
- 13.4.5.1 Harm-reduction policy, workplace safety regulation, and roadside testing to drive drug screening market
- 13.4.6 SOUTH KOREA
- 13.4.6.1 Zero-tolerance drug policy, mandatory military service, and forensic-grade testing to shape drug screening market
- 13.4.7 REST OF ASIA PACIFIC
- 13.5 LATIN AMERICA
- 13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
- 13.5.2 BRAZIL
- 13.5.2.1 Brazil's drug screening market to expand amid road safety mandates, substance-use burden, and regulatory enforcement
- 13.5.3 MEXICO
- 13.5.3.1 Mexico's drug screening market shaped by methamphetamine prevalence, cross-border labor dynamics, and public safety enforcement
- 13.5.4 REST OF LATIN AMERICA
- 13.6 MIDDLE EAST & AFRICA
- 13.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
- 13.6.2 GCC COUNTRIES
- 13.6.2.1 Saudi Arabia
- 13.6.2.1.1 Public safety, diagnostic modernization, and evolving consumption patterns to boost market
- 13.6.2.2 UAE
- 13.6.2.2.1 Integrated safety enforcement, workplace testing, and diagnostic modernization to expand market in UAE
- 13.6.2.3 Rest of GCC Countries
- 13.6.2.1 Saudi Arabia
- 13.6.3 SOUTH AFRICA
- 13.6.3.1 Rising substance use, workplace risk management, and advanced screening capabilities to fuel market growth
- 13.6.4 REST OF MIDDLE EAST & AFRICA
14 COMPETITIVE LANDSCAPE
- 14.1 OVERVIEW
- 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
- 14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG SCREENING MARKET
- 14.3 REVENUE ANALYSIS, 2020-2024
- 14.4 MARKET SHARE ANALYSIS, 2024
- 14.5 BRAND COMPARISON
- 14.6 COMPANY VALUATION & FINANCIAL METRICS
- 14.6.1 FINANCIAL METRICS
- 14.6.2 COMPANY VALUATION
- 14.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
- 14.7.1 STARS
- 14.7.2 EMERGING LEADERS
- 14.7.3 PERVASIVE PLAYERS
- 14.7.4 PARTICIPANTS
- 14.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
- 14.7.5.1 Company footprint
- 14.7.5.2 Region footprint
- 14.7.5.3 Offering footprint
- 14.7.5.4 Sample type footprint
- 14.7.5.5 Drug type footprint
- 14.7.5.6 End-user footprint
- 14.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
- 14.8.1 PROGRESSIVE COMPANIES
- 14.8.2 RESPONSIVE COMPANIES
- 14.8.3 DYNAMIC COMPANIES
- 14.8.4 STARTING BLOCKS
- 14.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
- 14.8.5.1 Detailed list of key startups/SMEs
- 14.8.5.2 Competitive benchmarking of startups/SMEs
- 14.9 COMPETITIVE SCENARIO
- 14.9.1 PRODUCT LAUNCHES & ENHANCEMENTS
- 14.9.2 DEALS
- 14.9.3 OTHER DEVELOPMENTS
15 COMPANY PROFILES
- 15.1 KEY PLAYERS
- 15.1.1 LABCORP
- 15.1.1.1 Business overview
- 15.1.1.2 Products & services offered
- 15.1.1.3 Recent developments
- 15.1.1.3.1 Deals
- 15.1.1.4 MnM view
- 15.1.1.4.1 Key strengths
- 15.1.1.4.2 Strategic choices
- 15.1.1.4.3 Weaknesses & competitive threats
- 15.1.2 QUEST DIAGNOSTICS INCORPORATED
- 15.1.2.1 Business overview
- 15.1.2.2 Products & services offered
- 15.1.2.3 Recent developments
- 15.1.2.3.1 Product & service launches
- 15.1.2.3.2 Deals
- 15.1.2.4 MnM view
- 15.1.2.4.1 Key strengths
- 15.1.2.4.2 Strategic choices
- 15.1.2.4.3 Weaknesses & competitive threats
- 15.1.3 ABBOTT
- 15.1.3.1 Business overview
- 15.1.3.2 Products & services offered
- 15.1.3.3 MnM view
- 15.1.3.3.1 Key strengths
- 15.1.3.3.2 Strategic choices
- 15.1.3.3.3 Weaknesses & competitive threats
- 15.1.4 ORASURE TECHNOLOGIES INC.
- 15.1.4.1 Business overview
- 15.1.4.2 Products & services offered
- 15.1.4.3 Recent developments
- 15.1.4.3.1 Deals
- 15.1.4.4 MnM view
- 15.1.4.4.1 Key strengths
- 15.1.4.4.2 Strategic choices
- 15.1.4.4.3 Weaknesses & competitive threats
- 15.1.5 ALFA SCIENTIFIC DESIGNS INC.
- 15.1.5.1 Business overview
- 15.1.5.2 Products & services offered
- 15.1.5.3 MnM view
- 15.1.5.3.1 Key strengths
- 15.1.5.3.2 Strategic choices
- 15.1.5.3.3 Weaknesses & competitive threats
- 15.1.6 THERMO FISHER SCIENTIFIC INC.
- 15.1.6.1 Business overview
- 15.1.6.2 Products & services offered
- 15.1.6.3 Recent developments
- 15.1.6.3.1 Product developments
- 15.1.6.3.2 Deals
- 15.1.7 DRAGERWERK AG & CO. KGAA
- 15.1.7.1 Business overview
- 15.1.7.2 Products & services offered
- 15.1.7.3 Recent developments
- 15.1.7.3.1 Product launches
- 15.1.8 LIFELOC TECHNOLOGIES, INC.
- 15.1.8.1 Business overview
- 15.1.8.2 Products & services offered
- 15.1.8.3 Recent developments
- 15.1.8.3.1 Other developments
- 15.1.9 MPD INC.
- 15.1.9.1 Business overview
- 15.1.9.2 Products & services offered
- 15.1.10 OMEGA LABORATORIES, INC.
- 15.1.10.1 Business overview
- 15.1.10.2 Products & services offered
- 15.1.10.3 Recent developments
- 15.1.10.3.1 Service launches
- 15.1.10.3.2 Deals
- 15.1.10.3.3 Other developments
- 15.1.11 PREMIER BIOTECH, INC.
- 15.1.11.1 Business overview
- 15.1.11.2 Products & services offered
- 15.1.11.3 Recent developments
- 15.1.11.3.1 Deals
- 15.1.12 PSYCHEMEDICS CORPORATION
- 15.1.12.1 Business overview
- 15.1.12.2 Products & services offered
- 15.1.12.3 Recent developments
- 15.1.12.3.1 Product launches & enhancements
- 15.1.12.3.2 Other developments
- 15.1.13 F. HOFFMANN-LA ROCHE LTD.
- 15.1.13.1 Business overview
- 15.1.13.2 Products & services offered
- 15.1.13.3 Recent developments
- 15.1.13.3.1 Deals
- 15.1.14 SHIMADZU CORPORATION
- 15.1.14.1 Business overview
- 15.1.14.2 Products & services offered
- 15.1.14.3 Recent developments
- 15.1.14.3.1 Product launches
- 15.1.14.3.2 Deals
- 15.1.15 SIEMENS HEALTHINEERS AG
- 15.1.15.1 Business overview
- 15.1.15.2 Products & services offered
- 15.1.15.3 Recent developments
- 15.1.15.3.1 Product launches
- 15.1.15.3.2 Deals
- 15.1.16 BIO-RAD LABORATORIES, INC.
- 15.1.16.1 Business overview
- 15.1.16.2 Products & services offered
- 15.1.16.3 Recent developments
- 15.1.16.3.1 Product enhancements
- 15.1.16.3.2 Deals
- 15.1.1 LABCORP
- 15.2 OTHER PLAYERS
- 15.2.1 CAREHEALTH AMERICA CORP.
- 15.2.2 ACCUSOURCEHR, INC.
- 15.2.3 CORDANT HEALTH SOLUTIONS
- 15.2.4 ADVACARE PHARMA
- 15.2.5 ACM GLOBAL LABORATORIES
- 15.2.6 MILLENNIUM HEALTH
- 15.2.7 CLINICAL REFERENCE LABORATORY, INC.
- 15.2.8 INTOXIMETERS
- 15.2.9 INTOXALOCK
16 RESEARCH METHODOLOGY
- 16.1 RESEARCH APPROACH
- 16.1.1 SECONDARY RESEARCH
- 16.1.1.1 Key data from secondary sources
- 16.1.2 PRIMARY RESEARCH
- 16.1.2.1 Primary sources
- 16.1.2.2 Key data from primary sources
- 16.1.2.3 Breakdown of primaries
- 16.1.2.4 Insights from primary experts
- 16.1.1 SECONDARY RESEARCH
- 16.2 RESEARCH METHODOLOGY DESIGN
- 16.3 MARKET SIZE ESTIMATION
- 16.4 MARKET BREAKDOWN & DATA TRIANGULATION
- 16.5 MARKET SHARE ESTIMATION
- 16.6 STUDY ASSUMPTIONS
- 16.7 RESEARCH LIMITATIONS
- 16.7.1 METHODOLOGY-RELATED LIMITATIONS
- 16.8 RISK ASSESSMENT
17 APPENDIX
- 17.1 DISCUSSION GUIDE
- 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 17.3 CUSTOMIZATION OPTIONS
- 17.4 RELATED REPORTS
- 17.5 AUTHOR DETAILS
List of Tables
- TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
- TABLE 2 KEY PRODUCT & SERVICE LAUNCHES FOR DRUG & ALCOHOL TESTING, 2022-2025
- TABLE 3 REGULATORY AUTHORITIES FOR DRUG & ALCOHOL TESTING PRODUCTS & SERVICES
- TABLE 4 DRUG SCREENING MARKET: PORTER'S FIVE FORCES ANALYSIS
- TABLE 5 DRUG SCREENING MARKET: ROLE IN ECOSYSTEM
- TABLE 6 INDICATIVE PRICING OF DRUG SCREENING PRODUCTS & SERVICES, BY TYPE, 2024 (USD)
- TABLE 7 INDICATIVE PRICING OF DRUG SCREENING PRODUCTS & SERVICES, BY REGION, 2024 (USD)
- TABLE 8 DRUG SCREENING MARKET: KEY CONFERENCES & EVENTS, 2026-2027
- TABLE 9 CASE 1: COMPREHENSIVE ORAL FLUID DUID TESTING PROGRAM
- TABLE 10 CASE 2: HIGH-THROUGHPUT GC-MS DRUG SCREENING IN FORENSIC URINE TESTING
- TABLE 11 CASE 3: ORAL FLUID DRUG TESTING IMPLEMENTATION IN A DRUG COURT PROGRAM
- TABLE 12 US-ADJUSTED RECIPROCAL TARIFF RATES
- TABLE 13 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR DRUG SCREENING MARKET
- TABLE 14 DRUG SCREENING MARKET: LIST OF PATENTS/PATENT APPLICATIONS
- TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE END USERS (%)
- TABLE 16 KEY BUYING CRITERIA FOR TOP THREE END USERS
- TABLE 17 UNMET NEEDS IN DRUG SCREENING MARKET
- TABLE 18 END-USER EXPECTATIONS IN DRUG SCREENING MARKET
- TABLE 19 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 20 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 21 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 22 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 23 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 24 REGULATORY SCENARIO OF NORTH AMERICA
- TABLE 25 REGULATORY SCENARIO OF EUROPE
- TABLE 26 REGULATORY SCENARIO OF ASIA PACIFIC
- TABLE 27 REGULATORY SCENARIO OF LATIN AMERICA
- TABLE 28 REGULATORY SCENARIO OF MIDDLE EAST & AFRICA
- TABLE 29 DRUG SCREENING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
- TABLE 30 DRUG SCREENING SERVICES MARKET: MAJOR PLAYERS & OFFERINGS
- TABLE 31 DRUG SCREENING SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 32 DRUG SCREENING SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
- TABLE 33 DRUG SCREENING MARKET FOR LABORATORY TESTING SERVICES, BY REGION, 2023-2030 (USD MILLION)
- TABLE 34 DRUG SCREENING MARKET FOR ON-SITE TESTING SERVICES, BY REGION, 2023-2030 (USD MILLION)
- TABLE 35 DRUG SCREENING PRODUCTS MARKET: MAJOR PLAYERS & OFFERINGS
- TABLE 36 DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 37 DRUG SCREENING PRODUCTS MARKET, BY REGION, 2023-2030 (USD MILLION)
- TABLE 38 DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY REGION, 2023-2030 (USD MILLION)
- TABLE 39 DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 40 DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 41 DRUG SCREENING MARKET FOR BREATHALYZERS, BY REGION, 2023-2030 (USD MILLION)
- TABLE 42 DRUG SCREENING MARKET FOR FUEL-CELL BREATHALYZERS, BY REGION, 2023-2030 (USD MILLION)
- TABLE 43 DRUG SCREENING MARKET FOR SEMICONDUCTOR BREATHALYZERS, BY REGION, 2023-2030 (USD MILLION)
- TABLE 44 DRUG SCREENING MARKET FOR OTHER BREATHALYZERS, BY REGION, 2023-2030 (USD MILLION)
- TABLE 45 DRUG SCREENING MARKET FOR IMMUNOASSAY ANALYZERS, BY REGION, 2023-2030 (USD MILLION)
- TABLE 46 DRUG SCREENING MARKET FOR CHROMATOGRAPHY INSTRUMENTS, BY REGION, 2023-2030 (USD MILLION)
- TABLE 47 DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023-2030 (USD MILLION)
- TABLE 48 DRUG SCREENING MARKET FOR HANDHELD BREATHALYZERS, BY REGION, 2023-2030 (USD MILLION)
- TABLE 49 DRUG SCREENING MARKET FOR BENCHTOP BREATHALYZERS, BY REGION, 2023-2030 (USD MILLION)
- TABLE 50 DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 51 DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY REGION, 2023-2030 (USD MILLION)
- TABLE 52 BLOOD SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 53 DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY REGION, 2023-2030 (USD MILLION)
- TABLE 54 DRUG SCREENING MARKET FOR DRUG TESTING CUPS, BY REGION, 2023-2030 (USD MILLION)
- TABLE 55 DRUG SCREENING MARKET FOR DIP CARDS, BY REGION, 2023-2030 (USD MILLION)
- TABLE 56 DRUG SCREENING MARKET FOR DRUG TESTING CASSETTES, BY REGION, 2023-2030 (USD MILLION)
- TABLE 57 DRUG SCREENING MARKET FOR ORAL FLUID TESTING DEVICES, BY REGION, 2023-2030 (USD MILLION)
- TABLE 58 DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 59 DRUG SCREENING MARKET FOR CONSUMABLES, BY REGION, 2023-2030 (USD MILLION)
- TABLE 60 DRUG SCREENING MARKET FOR ASSAY KITS, BY REGION, 2023-2030 (USD MILLION)
- TABLE 61 DRUG SCREENING MARKET FOR SAMPLE COLLECTION DEVICES, BY REGION, 2023-2030 (USD MILLION)
- TABLE 62 DRUG SCREENING MARKET FOR CALIBRATORS & CONTROLS, BY REGION, 2023-2030 (USD MILLION)
- TABLE 63 DRUG SCREENING MARKET FOR OTHER CONSUMABLES, BY REGION, 2023-2030 (USD MILLION)
- TABLE 64 DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
- TABLE 65 DRUG SCREENING MARKET FOR URINE SAMPLES: MAJOR PLAYERS & OFFERINGS
- TABLE 66 DRUG SCREENING MARKET FOR URINE SAMPLES, BY REGION, 2023-2030 (USD MILLION)
- TABLE 67 DRUG SCREENING MARKET FOR BREATH SAMPLES: MAJOR PLAYERS & OFFERINGS
- TABLE 68 DRUG SCREENING MARKET FOR BREATH SAMPLES, BY REGION, 2023-2030 (USD MILLION)
- TABLE 69 DRUG SCREENING MARKET FOR ORAL FLUID SAMPLES: MAJOR PLAYERS & OFFERINGS
- TABLE 70 DRUG SCREENING MARKET FOR ORAL FLUID SAMPLES, BY REGION, 2023-2030 (USD MILLION)
- TABLE 71 DRUG SCREENING MARKET FOR HAIR SAMPLES: MAJOR PLAYERS & OFFERINGS
- TABLE 72 DRUG SCREENING MARKET FOR HAIR SAMPLES, BY REGION, 2023-2030 (USD MILLION)
- TABLE 73 DRUG SCREENING MARKET FOR OTHER SAMPLES: MAJOR PLAYERS & OFFERINGS
- TABLE 74 DRUG SCREENING MARKET FOR OTHER SAMPLES, BY REGION, 2023-2030 (USD MILLION)
- TABLE 75 DRUG SCREENING MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
- TABLE 76 DRUG SCREENING MARKET FOR CANNABIS: MAJOR PLAYERS & OFFERINGS
- TABLE 77 DRUG SCREENING MARKET FOR CANNABIS, BY REGION, 2023-2030 (USD MILLION)
- TABLE 78 DRUG SCREENING MARKET FOR ALCOHOL: MAJOR PLAYERS & OFFERINGS
- TABLE 79 DRUG SCREENING MARKET FOR ALCOHOL, BY REGION, 2023-2030 (USD MILLION)
- TABLE 80 DRUG SCREENING MARKET FOR COCAINE: MAJOR PLAYERS & OFFERINGS
- TABLE 81 DRUG SCREENING MARKET FOR COCAINE, BY REGION, 2023-2030 (USD MILLION)
- TABLE 82 DRUG SCREENING MARKET FOR OPIOIDS: MAJOR PLAYERS & OFFERINGS
- TABLE 83 DRUG SCREENING MARKET FOR OPIDS, BY REGION, 2023-2030 (USD MILLION)
- TABLE 84 DRUG SCREENING MARKET FOR AMPHETAMINES & METHAMPHETAMINES: MAJOR PLAYERS & OFFERINGS
- TABLE 85 DRUG SCREENING MARKET FOR AMPHETAMINES & METHAMPHETAMINES, BY REGION, 2023-2030 (USD MILLION)
- TABLE 86 DRUG SCREENING MARKET FOR OTHER DRUGS: MAJOR PLAYERS & OFFERINGS
- TABLE 87 DRUG SCREENING MARKET FOR OTHER DRUGS, BY REGION, 2023-2030 (USD MILLION)
- TABLE 88 DRUG SCREENING MARKET, BY END USER, 2023-2030 (USD MILLION)
- TABLE 89 DRUG SCREENING MARKET FOR DRUG TESTING LABORATORIES: MAJOR PLAYERS & OFFERINGS
- TABLE 90 DRUG SCREENING MARKET FOR DRUG TESTING LABORATORIES, BY REGION, 2023-2030 (USD MILLION)
- TABLE 91 DRUG SCREENING MARKET FOR WORKPLACES: MAJOR PLAYERS & OFFERINGS
- TABLE 92 DRUG SCREENING MARKET FOR WORKPLACES, BY REGION, 2023-2030 (USD MILLION)
- TABLE 93 US: DRUG SCREENING MARKET FOR WORKPLACES, BY TYPE, 2019-2026 (USD MILLION)
- TABLE 94 DRUG SCREENING MARKET FOR CRIMINAL JUSTICE SYSTEMS & LAW ENFORCEMENT AGENCIES: MAJOR PLAYERS & OFFERINGS
- TABLE 95 DRUG SCREENING MARKET FOR CRIMINAL JUSTICE SYSTEMS & LAW ENFORCEMENT AGENCIES, BY REGION, 2023-2030 (USD MILLION)
- TABLE 96 DRUG SCREENING MARKET FOR HOSPITALS: MAJOR PLAYERS & OFFERINGS
- TABLE 97 DRUG SCREENING MARKET FOR HOSPITALS, BY REGION, 2023-2030 (USD MILLION)
- TABLE 98 DRUG SCREENING MARKET FOR DRUG TREATMENT CENTERS: MAJOR PLAYERS & OFFERINGS
- TABLE 99 DRUG SCREENING MARKET FOR DRUG TREATMENT CENTERS, BY REGION, 2023-2030 (USD MILLION)
- TABLE 100 DRUG SCREENING MARKET FOR INDIVIDUAL USERS: MAJOR PLAYERS & OFFERINGS
- TABLE 101 DRUG SCREENING MARKET FOR INDIVIDUAL USERS, BY REGION, 2023-2030 (USD MILLION)
- TABLE 102 DRUG SCREENING MARKET FOR PAIN MANAGEMENT CENTERS: MAJOR PLAYERS & OFFERINGS
- TABLE 103 DRUG SCREENING MARKET FOR PAIN MANAGEMENT CENTERS, BY REGION, 2023-2030 (USD MILLION)
- TABLE 104 DRUG SCREENING MARKET FOR SCHOOLS & COLLEGES: MAJOR PLAYERS & OFFERINGS
- TABLE 105 DRUG SCREENING MARKET FOR SCHOOLS & COLLEGES, BY REGION, 2023-2030 (USD MILLION)
- TABLE 106 DRUG SCREENING MARKET FOR OTHER END USERS: MAJOR PLAYERS & OFFERINGS
- TABLE 107 DRUG SCREENING MARKET FOR OTHER END USERS, BY REGION, 2023-2030 (USD MILLION)
- TABLE 108 DRUG SCREENING MARKET, BY REGION, 2023-2030 (USD MILLION)
- TABLE 109 NORTH AMERICA: MACROECONOMIC INDICATORS
- TABLE 110 NORTH AMERICA: DRUG SCREENING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
- TABLE 111 NORTH AMERICA: DRUG SCREENING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
- TABLE 112 NORTH AMERICA: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 113 NORTH AMERICA: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 114 NORTH AMERICA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 115 NORTH AMERICA: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 116 NORTH AMERICA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023-2030 (USD MILLION)
- TABLE 117 NORTH AMERICA: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 118 NORTH AMERICA: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 119 NORTH AMERICA: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 120 NORTH AMERICA: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
- TABLE 121 NORTH AMERICA: DRUG SCREENING MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
- TABLE 122 NORTH AMERICA: DRUG SCREENING MARKET, BY END USER, 2023-2030 (USD MILLION)
- TABLE 123 US: DRUG SCREENING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
- TABLE 124 US: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 125 US: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 126 US: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 127 US: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 128 US: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023-2030 (USD MILLION)
- TABLE 129 US: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 130 US: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 131 US: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 132 US: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
- TABLE 133 US: DRUG SCREENING MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
- TABLE 134 US: DRUG SCREENING MARKET, BY END USER, 2023-2030 (USD MILLION)
- TABLE 135 CANADA: DRUG SCREENING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
- TABLE 136 CANADA: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 137 CANADA: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 138 CANADA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 139 CANADA: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 140 CANADA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023-2030 (USD MILLION)
- TABLE 141 CANADA: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 142 CANADA: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 143 CANADA: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 144 CANADA: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
- TABLE 145 CANADA: DRUG SCREENING MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
- TABLE 146 CANADA: DRUG SCREENING MARKET, BY END USER, 2023-2030 (USD MILLION)
- TABLE 147 EUROPE: MACROECONOMIC INDICATORS
- TABLE 148 EUROPE: DRUG SCREENING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
- TABLE 149 EUROPE: DRUG SCREENING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
- TABLE 150 EUROPE: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 151 EUROPE: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 152 EUROPE: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 153 EUROPE: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 154 EUROPE: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023-2030 (USD MILLION)
- TABLE 155 EUROPE: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 156 EUROPE: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 157 EUROPE: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 158 EUROPE: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
- TABLE 159 EUROPE: DRUG SCREENING MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
- TABLE 160 EUROPE: DRUG SCREENING MARKET, BY END USER, 2023-2030 (USD MILLION)
- TABLE 161 GERMANY: DRUG SCREENING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
- TABLE 162 GERMANY: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 163 GERMANY: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 164 GERMANY: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 165 GERMANY: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 166 GERMANY: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023-2030 (USD MILLION)
- TABLE 167 GERMANY: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 168 GERMANY: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 169 GERMANY: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 170 GERMANY: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
- TABLE 171 GERMANY: DRUG SCREENING MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
- TABLE 172 GERMANY: DRUG SCREENING MARKET, BY END USER, 2023-2030 (USD MILLION)
- TABLE 173 FRANCE: DRUG SCREENING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
- TABLE 174 FRANCE: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 175 FRANCE: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 176 FRANCE: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 177 FRANCE: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 178 FRANCE: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023-2030 (USD MILLION)
- TABLE 179 FRANCE: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 180 FRANCE: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 181 FRANCE: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 182 FRANCE: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
- TABLE 183 FRANCE: DRUG SCREENING MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
- TABLE 184 FRANCE: DRUG SCREENING MARKET, BY END USER, 2023-2030 (USD MILLION)
- TABLE 185 UK: DRUG SCREENING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
- TABLE 186 UK: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 187 UK: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 188 UK: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 189 UK: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 190 UK: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023-2030 (USD MILLION)
- TABLE 191 UK: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 192 UK: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 193 UK: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 194 UK: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
- TABLE 195 UK: DRUG SCREENING MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
- TABLE 196 UK: DRUG SCREENING MARKET, BY END USER, 2023-2030 (USD MILLION)
- TABLE 197 ITALY: DRUG SCREENING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
- TABLE 198 ITALY: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 199 ITALY: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 200 ITALY: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 201 ITALY: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 202 ITALY: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023-2030 (USD MILLION)
- TABLE 203 ITALY: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 204 ITALY: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 205 ITALY: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 206 ITALY: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
- TABLE 207 ITALY: DRUG SCREENING MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
- TABLE 208 ITALY: DRUG SCREENING MARKET, BY END USER, 2023-2030 (USD MILLION)
- TABLE 209 SPAIN: DRUG SCREENING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
- TABLE 210 SPAIN: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 211 SPAIN: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 212 SPAIN: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 213 SPAIN: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 214 SPAIN: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023-2030 (USD MILLION)
- TABLE 215 SPAIN: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 216 SPAIN: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 217 SPAIN: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 218 SPAIN: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
- TABLE 219 SPAIN: DRUG SCREENING MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
- TABLE 220 SPAIN: DRUG SCREENING MARKET, BY END USER, 2023-2030 (USD MILLION)
- TABLE 221 REST OF EUROPE: DRUG SCREENING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
- TABLE 222 REST OF EUROPE: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 223 REST OF EUROPE: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 224 REST OF EUROPE: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 225 REST OF EUROPE: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 226 REST OF EUROPE: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023-2030 (USD MILLION)
- TABLE 227 REST OF EUROPE: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 228 REST OF EUROPE: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 229 REST OF EUROPE: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 230 REST OF EUROPE: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
- TABLE 231 REST OF EUROPE: DRUG SCREENING MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
- TABLE 232 REST OF EUROPE: DRUG SCREENING MARKET, BY END USER, 2023-2030 (USD MILLION)
- TABLE 233 ASIA PACIFIC: MACROECONOMIC INDICATORS
- TABLE 234 ASIA PACIFIC: DRUG SCREENING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
- TABLE 235 ASIA PACIFIC: DRUG SCREENING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
- TABLE 236 ASIA PACIFIC: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 237 ASIA PACIFIC: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 238 ASIA PACIFIC: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 239 ASIA PACIFIC: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 240 ASIA PACIFIC: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023-2030 (USD MILLION)
- TABLE 241 ASIA PACIFIC: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 242 ASIA PACIFIC: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 243 ASIA PACIFIC: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 244 ASIA PACIFIC: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
- TABLE 245 ASIA PACIFIC: DRUG SCREENING MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
- TABLE 246 ASIA PACIFIC: DRUG SCREENING MARKET, BY END USER, 2023-2030 (USD MILLION)
- TABLE 247 CHINA: DRUG SCREENING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
- TABLE 248 CHINA: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 249 CHINA: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 250 CHINA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 251 CHINA: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 252 CHINA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023-2030 (USD MILLION)
- TABLE 253 CHINA: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 254 CHINA: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 255 CHINA: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 256 CHINA: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
- TABLE 257 CHINA: DRUG SCREENING MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
- TABLE 258 CHINA: DRUG SCREENING MARKET, BY END USER, 2023-2030 (USD MILLION)
- TABLE 259 JAPAN: DRUG SCREENING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
- TABLE 260 JAPAN: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 261 JAPAN: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 262 JAPAN: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 263 JAPAN: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 264 JAPAN: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023-2030 (USD MILLION)
- TABLE 265 JAPAN: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 266 JAPAN: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 267 JAPAN: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 268 JAPAN: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
- TABLE 269 JAPAN: DRUG SCREENING MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
- TABLE 270 JAPAN: DRUG SCREENING MARKET, BY END USER, 2023-2030 (USD MILLION)
- TABLE 271 INDIA: DRUG SCREENING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
- TABLE 272 INDIA: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 273 INDIA: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 274 INDIA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 275 INDIA: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 276 INDIA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023-2030 (USD MILLION)
- TABLE 277 INDIA: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 278 INDIA: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 279 INDIA: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 280 INDIA: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
- TABLE 281 INDIA: DRUG SCREENING MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
- TABLE 282 INDIA: DRUG SCREENING MARKET, BY END USER, 2023-2030 (USD MILLION)
- TABLE 283 AUSTRALIA: DRUG SCREENING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
- TABLE 284 AUSTRALIA: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 285 AUSTRALIA: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 286 AUSTRALIA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 287 AUSTRALIA: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 288 AUSTRALIA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023-2030 (USD MILLION)
- TABLE 289 AUSTRALIA: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 290 AUSTRALIA: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 291 AUSTRALIA: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 292 AUSTRALIA: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
- TABLE 293 AUSTRALIA: DRUG SCREENING MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
- TABLE 294 AUSTRALIA: DRUG SCREENING MARKET, BY END USER, 2023-2030 (USD MILLION)
- TABLE 295 SOUTH KOREA: DRUG SCREENING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
- TABLE 296 SOUTH KOREA: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 297 SOUTH KOREA: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 298 SOUTH KOREA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 299 SOUTH KOREA: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 300 SOUTH KOREA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023-2030 (USD MILLION)
- TABLE 301 SOUTH KOREA: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 302 SOUTH KOREA: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 303 SOUTH KOREA: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 304 SOUTH KOREA: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
- TABLE 305 SOUTH KOREA: DRUG SCREENING MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
- TABLE 306 SOUTH KOREA: DRUG SCREENING MARKET, BY END USER, 2023-2030 (USD MILLION)
- TABLE 307 REST OF ASIA PACIFIC: DRUG SCREENING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
- TABLE 308 REST OF ASIA PACIFIC: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 309 REST OF ASIA PACIFIC: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 310 REST OF ASIA PACIFIC: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 311 REST OF ASIA PACIFIC: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 312 REST OF ASIA PACIFIC: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023-2030 (USD MILLION)
- TABLE 313 REST OF ASIA PACIFIC: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 314 REST OF ASIA PACIFIC: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 315 REST OF ASIA PACIFIC: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 316 REST OF ASIA PACIFIC: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
- TABLE 317 REST OF ASIA PACIFIC: DRUG SCREENING MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
- TABLE 318 REST OF ASIA PACIFIC: DRUG SCREENING MARKET, BY END USER, 2023-2030 (USD MILLION)
- TABLE 319 LATIN AMERICA: MACROECONOMIC INDICATORS
- TABLE 320 LATIN AMERICA: DRUG SCREENING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
- TABLE 321 LATIN AMERICA: DRUG SCREENING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
- TABLE 322 LATIN AMERICA: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 323 LATIN AMERICA: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 324 LATIN AMERICA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 325 LATIN AMERICA: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 326 LATIN AMERICA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023-2030 (USD MILLION)
- TABLE 327 LATIN AMERICA: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 328 LATIN AMERICA: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 329 LATIN AMERICA: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 330 LATIN AMERICA: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
- TABLE 331 LATIN AMERICA: DRUG SCREENING MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
- TABLE 332 LATIN AMERICA: DRUG SCREENING MARKET, BY END USER, 2023-2030 (USD MILLION)
- TABLE 333 BRAZIL: DRUG SCREENING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
- TABLE 334 BRAZIL: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 335 BRAZIL: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 336 BRAZIL: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 337 BRAZIL: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 338 BRAZIL: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023-2030 (USD MILLION)
- TABLE 339 BRAZIL: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 340 BRAZIL: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 341 BRAZIL: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 342 BRAZIL: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
- TABLE 343 BRAZIL: DRUG SCREENING MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
- TABLE 344 BRAZIL: DRUG SCREENING MARKET, BY END USER, 2023-2030 (USD MILLION)
- TABLE 345 MEXICO: DRUG SCREENING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
- TABLE 346 MEXICO: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 347 MEXICO: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 348 MEXICO: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 349 MEXICO: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 350 MEXICO: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023-2030 (USD MILLION)
- TABLE 351 MEXICO: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 352 MEXICO: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 353 MEXICO: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 354 MEXICO: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
- TABLE 355 MEXICO: DRUG SCREENING MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
- TABLE 356 MEXICO: DRUG SCREENING MARKET, BY END USER, 2023-2030 (USD MILLION)
- TABLE 357 REST OF LATIN AMERICA: DRUG SCREENING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
- TABLE 358 REST OF LATIN AMERICA: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 359 REST OF LATIN AMERICA: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 360 REST OF LATIN AMERICA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 361 REST OF LATIN AMERICA: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 362 REST OF LATIN AMERICA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023-2030 (USD MILLION)
- TABLE 363 REST OF LATIN AMERICA: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 364 REST OF LATIN AMERICA: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 365 REST OF LATIN AMERICA: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 366 REST OF LATIN AMERICA: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
- TABLE 367 REST OF LATIN AMERICA: DRUG SCREENING MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
- TABLE 368 REST OF LATIN AMERICA: DRUG SCREENING MARKET, BY END USER, 2023-2030 (USD MILLION)
- TABLE 369 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
- TABLE 370 MIDDLE EAST & AFRICA: DRUG SCREENING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
- TABLE 371 MIDDLE EAST & AFRICA: DRUG SCREENING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
- TABLE 372 MIDDLE EAST & AFRICA: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 373 MIDDLE EAST & AFRICA: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 374 MIDDLE EAST & AFRICA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE,2023-2030 (USD MILLION)
- TABLE 375 MIDDLE EAST & AFRICA: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 376 MIDDLE EAST & AFRICA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023-2030 (USD MILLION)
- TABLE 377 MIDDLE EAST & AFRICA: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 378 MIDDLE EAST & AFRICA: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 379 MIDDLE EAST & AFRICA: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 380 MIDDLE EAST & AFRICA: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
- TABLE 381 MIDDLE EAST & AFRICA: DRUG SCREENING MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
- TABLE 382 MIDDLE EAST & AFRICA: DRUG SCREENING MARKET, BY END USER, 2023-2030 (USD MILLION)
- TABLE 383 GCC COUNTRIES: DRUG SCREENING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
- TABLE 384 GCC COUNTRIES: DRUG SCREENING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
- TABLE 385 GCC COUNTRIES: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 386 GCC COUNTRIES: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 387 GCC COUNTRIES: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 388 GCC COUNTRIES: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 389 GCC COUNTRIES: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023-2030 (USD MILLION)
- TABLE 390 GCC COUNTRIES: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 391 GCC COUNTRIES: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 392 GCC COUNTRIES: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 393 GCC COUNTRIES: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
- TABLE 394 GCC COUNTRIES: DRUG SCREENING MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
- TABLE 395 GCC COUNTRIES: DRUG SCREENING MARKET, BY END USER, 2023-2030 (USD MILLION)
- TABLE 396 SAUDI ARABIA: DRUG SCREENING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
- TABLE 397 SAUDI ARABIA: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 398 SAUDI ARABIA: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 399 SAUDI ARABIA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 400 SAUDI ARABIA: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 401 SAUDI ARABIA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023-2030 (USD MILLION)
- TABLE 402 SAUDI ARABIA: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 403 SAUDI ARABIA: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 404 SAUDI ARABIA: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 405 SAUDI ARABIA: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
- TABLE 406 SAUDI ARABIA: DRUG SCREENING MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
- TABLE 407 SAUDI ARABIA: DRUG SCREENING MARKET, BY END USER, 2023-2030 (USD MILLION)
- TABLE 408 UAE: DRUG SCREENING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
- TABLE 409 UAE: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 410 UAE: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 411 UAE: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 412 UAE: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 413 UAE: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023-2030 (USD MILLION)
- TABLE 414 UAE: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 415 UAE: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 416 UAE: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 417 UAE: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
- TABLE 418 UAE: DRUG SCREENING MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
- TABLE 419 UAE: DRUG SCREENING MARKET, BY END USER, 2023-2030 (USD MILLION)
- TABLE 420 REST OF GCC COUNTRIES: DRUG SCREENING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
- TABLE 421 REST OF GCC COUNTRIES: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 422 REST OF GCC COUNTRIES: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 423 REST OF GCC COUNTRIES: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 424 REST OF GCC COUNTRIES: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 425 REST OF GCC COUNTRIES: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023-2030 (USD MILLION)
- TABLE 426 REST OF GCC COUNTRIES: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 427 REST OF GCC COUNTRIES: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 428 REST OF GCC COUNTRIES: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 429 REST OF GCC COUNTRIES: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
- TABLE 430 REST OF GCC COUNTRIES: DRUG SCREENING MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
- TABLE 431 REST OF GCC COUNTRIES: DRUG SCREENING MARKET, BY END USER, 2023-2030 (USD MILLION)
- TABLE 432 SOUTH AFRICA: DRUG SCREENING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
- TABLE 433 SOUTH AFRICA: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 434 SOUTH AFRICA: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 435 SOUTH AFRICA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 436 SOUTH AFRICA: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 437 SOUTH AFRICA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023-2030 (USD MILLION)
- TABLE 438 SOUTH AFRICA: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 439 SOUTH AFRICA: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 440 SOUTH AFRICA: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 441 SOUTH AFRICA: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
- TABLE 442 SOUTH AFRICA: DRUG SCREENING MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
- TABLE 443 SOUTH AFRICA: DRUG SCREENING MARKET, BY END USER, 2023-2030 (USD MILLION)
- TABLE 444 REST OF MIDDLE EAST & AFRICA: DRUG SCREENING MARKET, BY OFFERING, 2023-2030 (USD MILLION)
- TABLE 445 REST OF MIDDLE EAST & AFRICA: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 446 REST OF MIDDLE EAST & AFRICA: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 447 REST OF MIDDLE EAST & AFRICA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 448 REST OF MIDDLE EAST & AFRICA: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 449 REST OF MIDDLE EAST & AFRICA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023-2030 (USD MILLION)
- TABLE 450 REST OF MIDDLE EAST & AFRICA: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 451 REST OF MIDDLE EAST & AFRICA: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 452 REST OF MIDDLE EAST & AFRICA: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023-2030 (USD MILLION)
- TABLE 453 REST OF MIDDLE EAST & AFRICA: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
- TABLE 454 REST OF MIDDLE EAST & AFRICA: DRUG SCREENING MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
- TABLE 455 REST OF MIDDLE EAST & AFRICA: DRUG SCREENING MARKET, BY END USER, 2023-2030 (USD MILLION)
- TABLE 456 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG SCREENING, JANUARY 2022-DECEMBER 2025
- TABLE 457 DRUG SCREENING MARKET: DEGREE OF COMPETITION
- TABLE 458 DRUG SCREENING MARKET: REGION FOOTPRINT
- TABLE 459 DRUG SCREENING MARKET: OFFERING FOOTPRINT
- TABLE 460 DRUG SCREENING MARKET: SAMPLE TYPE FOOTPRINT
- TABLE 461 DRUG SCREENING MARKET: DRUG TYPE FOOTPRINT
- TABLE 462 DRUG SCREENING MARKET: END-USER FOOTPRINT
- TABLE 463 DRUG SCREENING MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
- TABLE 464 DRUG SCREENING MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY REGION
- TABLE 465 DRUG SCREENING MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY OFFERING
- TABLE 466 DRUG SCREENING MARKET: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2022- DECEMBER 2025
- TABLE 467 DRUG SCREENING MARKET: DEALS, JANUARY 2022-DECEMBER 2025
- TABLE 468 DRUG SCREENING MARKET: OTHER DEVELOPMENTS, JANUARY 2022-DECEMBER 2025
- TABLE 469 LABCORP: COMPANY OVERVIEW
- TABLE 470 LABCORP: PRODUCTS & SERVICES OFFERED
- TABLE 471 LABCORP: DEALS, JANUARY 2022-DECEMBER 2025
- TABLE 472 QUEST DIAGNOSTICS INCORPORATED: COMPANY OVERVIEW
- TABLE 473 QUEST DIAGNOSTICS INCORPORATED: PRODUCTS & SERVICES OFFERED
- TABLE 474 QUEST DIAGNOSTICS INCORPORATED: PRODUCT & SERVICE LAUNCHES, JANUARY 2022-DECEMBER 2025
- TABLE 475 QUEST DIAGNOSTICS INCORPORATED: DEALS, JANUARY 2022-DECEMBER 2025
- TABLE 476 ABBOTT: COMPANY OVERVIEW
- TABLE 477 ABBOTT: PRODUCTS & SERVICES OFFERED
- TABLE 478 ORASURE TECHNOLOGIES INC.: COMPANY OVERVIEW
- TABLE 479 ORASURE TECHNOLOGIES INC.: PRODUCTS & SERVICES OFFERED
- TABLE 480 ORASURE TECHNOLOGIES INC.: DEALS, JANUARY 2022-DECEMBER 2025
- TABLE 481 ALFA SCIENTIFIC DESIGNS INC.: COMPANY OVERVIEW
- TABLE 482 ALFA SCIENTIFIC DESIGNS INC.: PRODUCTS & SERVICES OFFERED
- TABLE 483 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
- TABLE 484 THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES OFFERED
- TABLE 485 THERMO FISHER SCIENTIFIC INC.: PRODUCT DEVELOPMENTS, JANUARY 2022-DECEMBER 2025
- TABLE 486 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022-DECEMBER 2025
- TABLE 487 DRAGERWERK AG & CO. KGAA: COMPANY OVERVIEW
- TABLE 488 DRAGERWERK AG & CO. KGAA: PRODUCTS & SERVICES OFFERED
- TABLE 489 DRAGERWERK AG & CO. KGAA: PRODUCT LAUNCHES, JANUARY 2022-DECEMBER 2025
- TABLE 490 LIFELOC TECHNOLOGIES, INC.: COMPANY OVERVIEW
- TABLE 491 LIFELOC TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED
- TABLE 492 LIFELOC TECHNOLOGIES, INC.: OTHER DEVELOPMENTS, JANUARY 2022-DECEMBER 2025
- TABLE 493 MPD INC.: COMPANY OVERVIEW
- TABLE 494 MPD INC.: PRODUCTS & SERVICES OFFERED
- TABLE 495 OMEGA LABORATORIES, INC.: COMPANY OVERVIEW
- TABLE 496 OMEGA LABORATORIES, INC.: PRODUCTS & SERVICES OFFERED
- TABLE 497 OMEGA LABORATORIES, INC.: SERVICE LAUNCHES, JANUARY 2022-DECEMBER 2025
- TABLE 498 OMEGA LABORATORIES, INC.: DEALS, JANUARY 2022-DECEMBER 2025
- TABLE 499 OMEGA LABORATORIES, INC.: OTHER DEVELOPMENTS, JANUARY 2022-DECEMBER 2025
- TABLE 500 PREMIER BIOTECH, INC.: COMPANY OVERVIEW
- TABLE 501 PREMIER BIOTECH, INC.: PRODUCTS & SERVICES OFFERED
- TABLE 502 PREMIER BIOTECH, INC.: DEALS, JANUARY 2022-DECEMBER 2025
- TABLE 503 PSYCHEMEDICS CORPORATION: COMPANY OVERVIEW
- TABLE 504 PSYCHEMEDICS CORPORATION: PRODUCTS & SERVICES OFFERED
- TABLE 505 PSYCHEMEDICS CORPORATION: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2022-DECEMBER 2025
- TABLE 506 PSYCHEMEDICS CORPORATION: OTHER DEVELOPMENTS, JANUARY 2022-DECEMBER 2025
- TABLE 507 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
- TABLE 508 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS & SERVICES OFFERED
- TABLE 509 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2022-DECEMBER 2025
- TABLE 510 SHIMADZU CORPORATION: COMPANY OVERVIEW
- TABLE 511 SHIMADZU CORPORATION: PRODUCTS & SERVICES OFFERED
- TABLE 512 SHIMADZU CORPORATION: PRODUCT LAUNCHES, JANUARY 2022-DECEMBER 2025
- TABLE 513 SHIMADZU CORPORATION: DEALS, JANUARY 2022-DECEMBER 2025
- TABLE 514 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
- TABLE 515 SIEMENS HEALTHINEERS AG: PRODUCTS & SERVICES OFFERED
- TABLE 516 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES, JANUARY 2022-DECEMBER 2025
- TABLE 517 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2022-DECEMBER 2025
- TABLE 518 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
- TABLE 519 BIO-RAD LABORATORIES, INC.: PRODUCTS & SERVICES OFFERED
- TABLE 520 BIO-RAD LABORATORIES, INC.: PRODUCT ENHANCEMENTS, JANUARY 2022-DECEMBER 2025
- TABLE 521 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2022-DECEMBER 2025
- TABLE 522 CAREHEALTH AMERICA CORP.: COMPANY OVERVIEW
- TABLE 523 ACCUSOURCEHR, INC.: COMPANY OVERVIEW
- TABLE 524 CORDANT HEALTH SOLUTIONS: COMPANY OVERVIEW
- TABLE 525 ADVACARE PHARMA: COMPANY OVERVIEW
- TABLE 526 ACM GLOBAL LABORATORIES: COMPANY OVERVIEW
- TABLE 527 MILLENNIUM HEALTH: COMPANY OVERVIEW
- TABLE 528 CLINICAL REFERENCE LABORATORY, INC.: COMPANY OVERVIEW
- TABLE 529 INTOXIMETERS: COMPANY OVERVIEW
- TABLE 530 INTOXALOCK: COMPANY OVERVIEW
- TABLE 531 RISK ASSESSMENT: DRUG SCREENING MARKET
List of Figures
- FIGURE 1 DRUG SCREENING MARKET SEGMENTATION & REGIONAL SCOPE
- FIGURE 2 MARKET SCENARIO
- FIGURE 3 GLOBAL DRUG SCREENING MARKET, 2023-2030
- FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG SCREENING MARKET, 2022-2025
- FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF DRUG SCREENING MARKET
- FIGURE 6 HIGH-GROWTH SEGMENTS IN DRUG SCREENING MARKET, 2025-2030
- FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN DRUG SCREENING MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
- FIGURE 8 EXPANDING WORKPLACE SAFETY MANDATES AND RISING SUBSTANCE ABUSE AWARENESS TO DRIVE MARKET GROWTH
- FIGURE 9 DRUG SCREENING PRODUCTS MARKET IN NORTH AMERICA ACCOUNTED FOR LARGEST SHARE IN 2024
- FIGURE 10 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
- FIGURE 11 GROWTH RATES OF EMERGING ECONOMIES TO BE HIGHER THAN THOSE OF DEVELOPED ECONOMIES DURING FORECAST PERIOD
- FIGURE 12 DRUG SCREENING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
- FIGURE 13 DRUG SCREENING MARKET: PORTER'S FIVE FORCES ANALYSIS
- FIGURE 14 DRUG SCREENING MARKET: VALUE CHAIN ANALYSIS (2024)
- FIGURE 15 DRUG SCREENING MARKET: ECOSYSTEM ANALYSIS
- FIGURE 16 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
- FIGURE 18 PATENT PUBLICATION TRENDS IN DRUG CREENING MARKET, 2015-2025
- FIGURE 19 JURISDICTION & TOP APPLICANT ANALYSIS FOR DRUG SCREENING MARKET
- FIGURE 20 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR DRUG SCREENING MARKET (JANUARY 2015 TO DECEMBER 2025)
- FIGURE 21 MARKET POTENTIAL OF AI/GEN AI ON DRUG SCREENING ACROSS INDUSTRIES
- FIGURE 22 IMPACT OF AI/GEN AI ON INTERCONNECTED & ADJACENT ECOSYSTEMS
- FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
- FIGURE 24 KEY BUYING CRITERIA FOR TOP THREE END USERS
- FIGURE 25 NORTH AMERICA: DRUG SCREENING MARKET SNAPSHOT
- FIGURE 26 ASIA PACIFIC: DRUG SCREENING MARKET SNAPSHOT
- FIGURE 27 REVENUE ANALYSIS OF KEY PLAYERS IN DRUG SCREENING MARKET, 2020-2024
- FIGURE 28 MARKET SHARE ANALYSIS OF KEY PLAYERS IN DRUG SCREENING MARKET, 2024
- FIGURE 29 DRUG SCREENING MARKET: BRAND COMPARATIVE ANALYSIS
- FIGURE 30 EV/EBITDA OF KEY VENDORS
- FIGURE 31 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
- FIGURE 32 DRUG SCREENING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
- FIGURE 33 DRUG SCREENING MARKET: COMPANY FOOTPRINT
- FIGURE 34 DRUG SCREENING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
- FIGURE 35 LABCORP: COMPANY SNAPSHOT (2024)
- FIGURE 36 QUEST DIAGNOSTICS INCORPORATED: COMPANY SNAPSHOT (2024)
- FIGURE 37 ABBOTT: COMPANY SNAPSHOT (2024)
- FIGURE 38 ORASURE TECHNOLOGIES INC.: COMPANY SNAPSHOT (2024)
- FIGURE 39 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
- FIGURE 40 DRAGERWERK AG & CO. KGAA: COMPANY SNAPSHOT (2024)
- FIGURE 41 LIFELOC TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024)
- FIGURE 42 PSYCHEMEDICS CORPORATION: COMPANY SNAPSHOT (2024)
- FIGURE 43 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024)
- FIGURE 44 SHIMADZU CORPORATION: COMPANY SNAPSHOT (2024)
- FIGURE 45 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2025)
- FIGURE 46 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2024)
- FIGURE 47 RESEARCH DESIGN
- FIGURE 48 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
- FIGURE 49 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
- FIGURE 50 BOTTOM-UP APPROACH
- FIGURE 51 TOP-DOWN APPROACH
- FIGURE 52 CAGR PROJECTIONS FROM ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN DRUG SCREENING INDUSTRY
- FIGURE 53 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
- FIGURE 54 DATA TRIANGULATION METHODOLOGY
02-2729-4219
+886-2-2729-4219
2026年全球藥物篩檢市場報告
日本藥物篩檢市場報告：按產品/服務、檢體類型、最終用戶和地區分類，2026-2034年
藥物篩檢市場規模、佔有率和成長分析（按產品類型、檢體類型、最終用途和地區分類）—產業預測（2026-2033 年）
藥物篩檢市場－全球產業規模、佔有率、趨勢、機會和預測，按產品和服務、樣本類型、最終用戶、地區和競爭格局分類，2020-2030年預測2025年全球藥物和酒精篩檢市場報告
藥物篩檢市場按技術、藥物類型、樣品類型和最終用戶分類－2025-2032年全球預測
藥物篩選市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測
藥物篩檢市場規模、佔有率、趨勢分析報告（按產品類型、樣品類型、最終用途、地區、細分市場預測），2025 年至 2030 年2025 年至 2033 年藥物篩選市場規模、佔有率、趨勢及預測（按產品和服務、樣本類型、最終用戶和地區）
全球藥物篩選市場規模：按產品類型、按樣本類型、按最終用戶、按地區、範圍和預測
▼